It isn't the most likely candidate to make someone a millionaire, but it's theoretically possible.With the company's market cap of $28 billion today, it's important to recognize that DexCom (DXCM -1.49%) is already one of the world's biggest medical device manufacturers. It therefore isn't likely to explode higher in value overnight, or even over the course of a couple of years.If it's going to be capable of making its investors into millionaires, those investors will need to commit a substantial amount of ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=104521&from=3 CLASS PERIOD: January 8, 2024 to J ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Sept. 23, 2024 /PRNewswire/ - ...

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=104029&from=4CLASS PERIOD: January 8, 2024 to July 25, ...

NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

文章核心观点 - 根据投资者诉讼,DexCom公司在2024年1月8日至7月25日期间存在证券欺诈行为,导致投资者遭受损失 [1][2] - 2024年7月25日,DexCom公司公布了2024财年第二季度的财务业绩,并下调了全年收入指引,公司将此归咎于"几项关键战略举措的执行未达预期" [2] - 投资者和分析师对DexCom的公告做出了即时反应,公司股价在7月26日下跌约40.66% [2] 公司相关 - DexCom是一家医疗设备公司,主要从事糖尿病连续监测系统的研发和生产 [1] - 公司股票代码为DXCM,在纳斯达克上市 [1] - 公司在2024年第二季度的财务业绩和全年收入指引低于预期 [2] 投资者诉讼相关 - 投资者诉讼针对2024年1月8日至7月25日期间的证券欺诈行为 [1] - 投资者如果在相关时间内遭受损失,可以在2024年10月21日之前申请担任首席原告 [2] - 原告无需支付任何费用即可获得赔偿 [3] - 律所Levi & Korsinsky在过去20年中为受害股东赢得了数亿美元的赔偿,在复杂证券诉讼方面拥有丰富经验 [3]

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...